Sanofi: Haemophilus Infections trials

The registry lists 36 Haemophilus Infections studies with Sanofi as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 2 2Phase 3 27Phase 4 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeCompletedNCT01659996Phase 4Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsCompletedNCT00831753Phase 3Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean InfantsCompletedNCT00831311Phase 2Results posted
• Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™CompletedNCT00802867Phase 4Results posted
• Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™CompletedNCT00772928Phase 3Results posted
• Retrospective Survey of Safety of Fourth Dose Pentacel® in ChildrenCompletedNCT00772369Results posted
• Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™CompletedNCT00654901Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™CompletedNCT00534833Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino InfantsCompletedNCT00514709Phase 3Results posted
• Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3Results posted
• Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3Results posted
• Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai InfantsCompletedNCT00401531Phase 3Results posted
• A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3Results posted
• Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPVCompletedNCT00362336Phase 3Results posted
• Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsCompletedNCT00348881Phase 3Results posted
• Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio VaccineCompletedNCT00343889Phase 3Results posted
• Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months ScheduleCompletedNCT00315055Phase 3Results posted
• Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.CompletedNCT00313911Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsCompletedNCT00303316Phase 3Results posted
• Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthCompletedNCT02428491Phase 3
• DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed InfantsCompletedNCT02094833Phase 3
• Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa VaccinationCompletedNCT01983540Phase 3
• Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.CompletedNCT01214889Phase 3
• A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy InfantsCompletedNCT01062477Phase 3
• Surveillance Program to Determine Product Specific Rates of Invasive Hib DiseaseCompletedNCT00855855
• Database Surveillance Safety Study of PENTACEL® VaccineCompletedNCT00804284
• Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended VaccineCompletedNCT00662870Phase 3
• Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 MonthsCompletedNCT00453570Phase 3
• Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®CompletedNCT00362427Phase 2
• Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®CompletedNCT00355654Phase 3
• Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
• Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
• Immunogenicity and Safety of Pentaxim™ in an Indian PopulationCompletedNCT00259337Phase 3
• Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandCompletedNCT00255021Phase 4
• Immunogenicity and Safety of Pentaxim in South African InfantsCompletedNCT00254969Phase 3
• Assessment of the Immunogenicity and Safety of PENTAXIM™ in PhilippinesCompletedNCT00254917Phase 4